- Home
- HNVR vs DERM Comparison
HNVR vs DERM Comparison
Compare HNVR & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- DERM
- Stock Information
- Founded
- HNVR 2008
- DERM 2014
- Country
- HNVR United States
- DERM United States
- Employees
- HNVR N/A
- DERM N/A
- Industry
- HNVR Commercial Banks
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- HNVR Finance
- DERM Health Care
- Exchange
- HNVR Nasdaq
- DERM Nasdaq
- Market Cap
- HNVR 167.7M
- DERM 165.6M
- IPO Year
- HNVR 2022
- DERM 2021
- Fundamental
- Price
- HNVR $21.51
- DERM $6.95
- Analyst Decision
- HNVR Buy
- DERM Strong Buy
- Analyst Count
- HNVR 2
- DERM 2
- Target Price
- HNVR $23.75
- DERM $12.50
- AVG Volume (30 Days)
- HNVR 12.4K
- DERM 185.6K
- Earning Date
- HNVR 07-23-2025
- DERM 08-12-2025
- Dividend Yield
- HNVR 1.86%
- DERM N/A
- EPS Growth
- HNVR N/A
- DERM N/A
- EPS
- HNVR 1.53
- DERM N/A
- Revenue
- HNVR $68,211,000.00
- DERM $56,397,000.00
- Revenue This Year
- HNVR N/A
- DERM $28.99
- Revenue Next Year
- HNVR $13.97
- DERM $52.61
- P/E Ratio
- HNVR $14.08
- DERM N/A
- Revenue Growth
- HNVR 14.14
- DERM N/A
- 52 Week Low
- HNVR $16.71
- DERM $3.54
- 52 Week High
- HNVR $27.14
- DERM $8.90
- Technical
- Relative Strength Index (RSI)
- HNVR 46.65
- DERM 44.00
- Support Level
- HNVR $20.88
- DERM $6.67
- Resistance Level
- HNVR $22.40
- DERM $8.90
- Average True Range (ATR)
- HNVR 0.57
- DERM 0.48
- MACD
- HNVR 0.08
- DERM -0.04
- Stochastic Oscillator
- HNVR 47.79
- DERM 12.56
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.